Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
Contineum Therapeutics stock drops as company prices upsized $90 million offering [Seeking Alpha]